vs
亚什兰（ASH）与CLOVER HEALTH INVESTMENTS, CORP.（CLOV）财务数据对比。点击上方公司名可切换其他公司
CLOVER HEALTH INVESTMENTS, CORP.的季度营收约是亚什兰的1.3倍（$487.7M vs $386.0M），亚什兰净利率更高（-3.1% vs -10.1%，领先7.0%），CLOVER HEALTH INVESTMENTS, CORP.同比增速更快（44.7% vs -4.7%），过去两年CLOVER HEALTH INVESTMENTS, CORP.的营收复合增速更高（17.0% vs -18.1%）
亚什兰是一家总部位于美国特拉华州威尔明顿的化工企业，1924年始创于肯塔基州亚什兰市，最初以炼油业务起家，1994年迁至现总部。公司拥有多个业务板块，覆盖化工中间体与溶剂、复合材料、工业特种化学品、个人及家居护理、制药、食品饮料以及农业相关领域，2017年之前曾是胜牌润滑油的主要生产商。
克利弗健康投资公司是2014年成立的美国医疗保健企业，主营联邦医疗保险优势计划保险产品，是与美国政府直接签约合作的机构。目前公司为美国11个州的联邦医疗保险参保人提供健康管理服务，并已于2021年1月8日公开上市。
ASH vs CLOV — 直观对比
营收规模更大
CLOV
是对方的1.3倍
$386.0M
营收增速更快
CLOV
高出49.4%
-4.7%
净利率更高
ASH
高出7.0%
-10.1%
两年增速更快
CLOV
近两年复合增速
-18.1%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $386.0M | $487.7M |
| 净利润 | $-12.0M | $-49.3M |
| 毛利率 | 27.2% | — |
| 营业利润率 | -1.6% | -10.1% |
| 净利率 | -3.1% | -10.1% |
| 营收同比 | -4.7% | 44.7% |
| 净利润同比 | 92.7% | -123.2% |
| 每股收益（稀释后） | $-0.26 | $-0.10 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASHCLOV
| Q1 26 | — | $487.7M | ||
| Q4 25 | $386.0M | $487.7M | ||
| Q3 25 | $477.0M | $496.6M | ||
| Q2 25 | $463.0M | $477.6M | ||
| Q1 25 | $479.0M | $462.3M | ||
| Q4 24 | $405.0M | $337.0M | ||
| Q3 24 | $521.0M | $331.0M | ||
| Q2 24 | $544.0M | $356.3M |
净利润ASHCLOV
| Q1 26 | — | $-49.3M | ||
| Q4 25 | $-12.0M | $-49.3M | ||
| Q3 25 | $31.0M | $-24.4M | ||
| Q2 25 | $-742.0M | $-10.6M | ||
| Q1 25 | $31.0M | $-1.3M | ||
| Q4 24 | $-165.0M | $-22.1M | ||
| Q3 24 | $17.0M | $-9.2M | ||
| Q2 24 | $6.0M | $7.4M |
毛利率ASHCLOV
| Q1 26 | — | — | ||
| Q4 25 | 27.2% | — | ||
| Q3 25 | 33.3% | — | ||
| Q2 25 | 28.5% | — | ||
| Q1 25 | 30.7% | — | ||
| Q4 24 | 27.4% | — | ||
| Q3 24 | 33.2% | 24.5% | ||
| Q2 24 | 34.2% | 30.3% |
营业利润率ASHCLOV
| Q1 26 | — | -10.1% | ||
| Q4 25 | -1.6% | -10.1% | ||
| Q3 25 | 12.8% | -4.9% | ||
| Q2 25 | -152.9% | -2.2% | ||
| Q1 25 | 10.6% | -0.3% | ||
| Q4 24 | -44.2% | -6.4% | ||
| Q3 24 | 6.1% | -2.7% | ||
| Q2 24 | -11.2% | 2.0% |
净利率ASHCLOV
| Q1 26 | — | -10.1% | ||
| Q4 25 | -3.1% | -10.1% | ||
| Q3 25 | 6.5% | -4.9% | ||
| Q2 25 | -160.3% | -2.2% | ||
| Q1 25 | 6.5% | -0.3% | ||
| Q4 24 | -40.7% | -6.6% | ||
| Q3 24 | 3.3% | -2.8% | ||
| Q2 24 | 1.1% | 2.1% |
每股收益（稀释后）ASHCLOV
| Q1 26 | — | $-0.10 | ||
| Q4 25 | $-0.26 | — | ||
| Q3 25 | $0.83 | — | ||
| Q2 25 | $-16.21 | — | ||
| Q1 25 | $0.65 | — | ||
| Q4 24 | $-3.50 | — | ||
| Q3 24 | $0.34 | — | ||
| Q2 24 | $0.12 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $304.0M | $95.3M |
| 总债务越低越好 | $1.4B | — |
| 股东权益账面价值 | $1.9B | $308.7M |
| 总资产 | $4.5B | $541.0M |
| 负债/权益比越低杠杆越低 | 0.74× | — |
8季度趋势，按日历期对齐
现金及短期投资ASHCLOV
| Q1 26 | — | $95.3M | ||
| Q4 25 | $304.0M | $78.3M | ||
| Q3 25 | $215.0M | — | ||
| Q2 25 | $207.0M | — | ||
| Q1 25 | $168.0M | — | ||
| Q4 24 | $219.0M | $194.5M | ||
| Q3 24 | $300.0M | $288.0M | ||
| Q2 24 | $399.0M | $254.8M |
总债务ASHCLOV
| Q1 26 | — | — | ||
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.3B | — | ||
| Q2 24 | $1.3B | — |
股东权益ASHCLOV
| Q1 26 | — | $308.7M | ||
| Q4 25 | $1.9B | $308.7M | ||
| Q3 25 | $1.9B | $340.9M | ||
| Q2 25 | $1.9B | $344.2M | ||
| Q1 25 | $2.6B | $336.1M | ||
| Q4 24 | $2.6B | $341.1M | ||
| Q3 24 | $2.9B | $342.2M | ||
| Q2 24 | $3.0B | $324.9M |
总资产ASHCLOV
| Q1 26 | — | $541.0M | ||
| Q4 25 | $4.5B | $541.0M | ||
| Q3 25 | $4.6B | $559.7M | ||
| Q2 25 | $4.6B | $575.0M | ||
| Q1 25 | $5.2B | $583.7M | ||
| Q4 24 | $5.2B | $580.7M | ||
| Q3 24 | $5.6B | $653.0M | ||
| Q2 24 | $5.7B | $674.2M |
负债/权益比ASHCLOV
| Q1 26 | — | — | ||
| Q4 25 | 0.74× | — | ||
| Q3 25 | 0.73× | — | ||
| Q2 25 | 0.73× | — | ||
| Q1 25 | 0.52× | — | ||
| Q4 24 | 0.51× | — | ||
| Q3 24 | 0.47× | — | ||
| Q2 24 | 0.45× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $125.0M | $0 |
| 自由现金流经营现金流 - 资本支出 | $111.0M | — |
| 自由现金流率自由现金流/营收 | 28.8% | — |
| 资本支出强度资本支出/营收 | 3.6% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $200.0M | — |
8季度趋势，按日历期对齐
经营现金流ASHCLOV
| Q1 26 | — | $0 | ||
| Q4 25 | $125.0M | $-66.9M | ||
| Q3 25 | $40.0M | $12.1M | ||
| Q2 25 | $115.0M | $5.4M | ||
| Q1 25 | $9.0M | $-16.3M | ||
| Q4 24 | $-30.0M | $34.8M | ||
| Q3 24 | $80.0M | $50.0M | ||
| Q2 24 | $127.0M | $44.8M |
自由现金流ASHCLOV
| Q1 26 | — | — | ||
| Q4 25 | $111.0M | $-69.0M | ||
| Q3 25 | $6.0M | $11.4M | ||
| Q2 25 | $95.0M | $4.8M | ||
| Q1 25 | $-12.0M | $-16.5M | ||
| Q4 24 | $-53.0M | $33.3M | ||
| Q3 24 | $42.0M | $49.6M | ||
| Q2 24 | $98.0M | $44.4M |
自由现金流率ASHCLOV
| Q1 26 | — | — | ||
| Q4 25 | 28.8% | -14.1% | ||
| Q3 25 | 1.3% | 2.3% | ||
| Q2 25 | 20.5% | 1.0% | ||
| Q1 25 | -2.5% | -3.6% | ||
| Q4 24 | -13.1% | 9.9% | ||
| Q3 24 | 8.1% | 15.0% | ||
| Q2 24 | 18.0% | 12.5% |
资本支出强度ASHCLOV
| Q1 26 | — | — | ||
| Q4 25 | 3.6% | 0.4% | ||
| Q3 25 | 7.1% | 0.1% | ||
| Q2 25 | 4.3% | 0.1% | ||
| Q1 25 | 4.4% | 0.0% | ||
| Q4 24 | 5.7% | 0.5% | ||
| Q3 24 | 7.3% | 0.1% | ||
| Q2 24 | 5.3% | 0.1% |
现金转化率ASHCLOV
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.29× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.29× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 4.71× | — | ||
| Q2 24 | 21.17× | 6.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASH
| Personal Care And Household | $123.0M | 32% |
| Other | $120.0M | 31% |
| Specialty Additives | $36.0M | 9% |
| Intermediates And Solvents | $31.0M | 8% |
| Personal Care | $30.0M | 8% |
| Life Sciences | $27.0M | 7% |
| Intermediates | $19.0M | 5% |
CLOV
暂无分部数据
